J wave syndrome-susceptibility mutations versus benign rare variants: How do we decide?

Jamie D. Kapplinger, David J. Tester, Michael John Ackerman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Over the past 20 years, the genetic underpinnings of J Wave Syndrome have expanded from the sentinel gene, SCN5A, to over 20 disease-susceptibility genes. Counter to the expansion of our understanding of the potential genetic basis underlying this disorder, our ability to confidently interpret the clinical significance of variants in these disease-susceptibility genes is desperately wanting. This is largely due to the drastic underestimation of the level of genetic variation in these genes as recently identified by large sequencing projects utilizing next generation sequencing technology. This “background rate” of benign genetic variation has led to an interpretive dilemma for the physician: How do we decide whether my patient’s variant is his/her pathogenic mutation or just a benign, rare one? Throughout this chapter, we walk through the current lines of evidence that can be utilized to further enhance the interpretation of rare variants in the J Wave Syndrome diseasesusceptibility genes.

Original languageEnglish (US)
Title of host publicationJ Wave Syndromes
Subtitle of host publicationBrugada and Early Repolarization Syndromes
PublisherSpringer International Publishing
Pages91-120
Number of pages30
ISBN (Electronic)9783319315782
ISBN (Print)9783319315768
DOIs
StatePublished - Jan 1 2016

Fingerprint

Genes
Mutation
Disease Susceptibility
Technology
Physicians

Keywords

  • Arrhythmias
  • Brugada syndrome
  • Early repolarization syndrome
  • Genetic testing
  • Genetics
  • J wave syndrome
  • Mutation
  • Polymorphism

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Kapplinger, J. D., Tester, D. J., & Ackerman, M. J. (2016). J wave syndrome-susceptibility mutations versus benign rare variants: How do we decide? In J Wave Syndromes: Brugada and Early Repolarization Syndromes (pp. 91-120). Springer International Publishing. https://doi.org/10.1007/978-3-319-31578-2_5

J wave syndrome-susceptibility mutations versus benign rare variants : How do we decide? / Kapplinger, Jamie D.; Tester, David J.; Ackerman, Michael John.

J Wave Syndromes: Brugada and Early Repolarization Syndromes. Springer International Publishing, 2016. p. 91-120.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kapplinger, JD, Tester, DJ & Ackerman, MJ 2016, J wave syndrome-susceptibility mutations versus benign rare variants: How do we decide? in J Wave Syndromes: Brugada and Early Repolarization Syndromes. Springer International Publishing, pp. 91-120. https://doi.org/10.1007/978-3-319-31578-2_5
Kapplinger JD, Tester DJ, Ackerman MJ. J wave syndrome-susceptibility mutations versus benign rare variants: How do we decide? In J Wave Syndromes: Brugada and Early Repolarization Syndromes. Springer International Publishing. 2016. p. 91-120 https://doi.org/10.1007/978-3-319-31578-2_5
Kapplinger, Jamie D. ; Tester, David J. ; Ackerman, Michael John. / J wave syndrome-susceptibility mutations versus benign rare variants : How do we decide?. J Wave Syndromes: Brugada and Early Repolarization Syndromes. Springer International Publishing, 2016. pp. 91-120
@inbook{4edce35129fb42b7ad24c6990b251c42,
title = "J wave syndrome-susceptibility mutations versus benign rare variants: How do we decide?",
abstract = "Over the past 20 years, the genetic underpinnings of J Wave Syndrome have expanded from the sentinel gene, SCN5A, to over 20 disease-susceptibility genes. Counter to the expansion of our understanding of the potential genetic basis underlying this disorder, our ability to confidently interpret the clinical significance of variants in these disease-susceptibility genes is desperately wanting. This is largely due to the drastic underestimation of the level of genetic variation in these genes as recently identified by large sequencing projects utilizing next generation sequencing technology. This “background rate” of benign genetic variation has led to an interpretive dilemma for the physician: How do we decide whether my patient’s variant is his/her pathogenic mutation or just a benign, rare one? Throughout this chapter, we walk through the current lines of evidence that can be utilized to further enhance the interpretation of rare variants in the J Wave Syndrome diseasesusceptibility genes.",
keywords = "Arrhythmias, Brugada syndrome, Early repolarization syndrome, Genetic testing, Genetics, J wave syndrome, Mutation, Polymorphism",
author = "Kapplinger, {Jamie D.} and Tester, {David J.} and Ackerman, {Michael John}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-31578-2_5",
language = "English (US)",
isbn = "9783319315768",
pages = "91--120",
booktitle = "J Wave Syndromes",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - J wave syndrome-susceptibility mutations versus benign rare variants

T2 - How do we decide?

AU - Kapplinger, Jamie D.

AU - Tester, David J.

AU - Ackerman, Michael John

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Over the past 20 years, the genetic underpinnings of J Wave Syndrome have expanded from the sentinel gene, SCN5A, to over 20 disease-susceptibility genes. Counter to the expansion of our understanding of the potential genetic basis underlying this disorder, our ability to confidently interpret the clinical significance of variants in these disease-susceptibility genes is desperately wanting. This is largely due to the drastic underestimation of the level of genetic variation in these genes as recently identified by large sequencing projects utilizing next generation sequencing technology. This “background rate” of benign genetic variation has led to an interpretive dilemma for the physician: How do we decide whether my patient’s variant is his/her pathogenic mutation or just a benign, rare one? Throughout this chapter, we walk through the current lines of evidence that can be utilized to further enhance the interpretation of rare variants in the J Wave Syndrome diseasesusceptibility genes.

AB - Over the past 20 years, the genetic underpinnings of J Wave Syndrome have expanded from the sentinel gene, SCN5A, to over 20 disease-susceptibility genes. Counter to the expansion of our understanding of the potential genetic basis underlying this disorder, our ability to confidently interpret the clinical significance of variants in these disease-susceptibility genes is desperately wanting. This is largely due to the drastic underestimation of the level of genetic variation in these genes as recently identified by large sequencing projects utilizing next generation sequencing technology. This “background rate” of benign genetic variation has led to an interpretive dilemma for the physician: How do we decide whether my patient’s variant is his/her pathogenic mutation or just a benign, rare one? Throughout this chapter, we walk through the current lines of evidence that can be utilized to further enhance the interpretation of rare variants in the J Wave Syndrome diseasesusceptibility genes.

KW - Arrhythmias

KW - Brugada syndrome

KW - Early repolarization syndrome

KW - Genetic testing

KW - Genetics

KW - J wave syndrome

KW - Mutation

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=85017640880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017640880&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-31578-2_5

DO - 10.1007/978-3-319-31578-2_5

M3 - Chapter

AN - SCOPUS:85017640880

SN - 9783319315768

SP - 91

EP - 120

BT - J Wave Syndromes

PB - Springer International Publishing

ER -